Summary
Pfizer Inc.'s 2024 Form 10-K highlights a year of revenue growth driven by key products like Paxlovid, the Seagen acquisition, and strong performance from the Vyndaqel family and Eliquis, despite a decline in Comirnaty revenues. Total revenues reached $63.6 billion, a 7% increase year-over-year, with operational growth contributing significantly. The company is strategically focused on improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation in 2025. Pfizer continues to navigate a complex regulatory and competitive landscape, including ongoing discussions around drug pricing, patent expirations for key products, and the integration of the Seagen acquisition, which is expected to generate significant synergies. Investors should note the potential impact of upcoming patent expiries between 2026 and 2030 on revenue streams, alongside ongoing efforts to bolster its product pipeline through internal development and strategic business development.
Financial Highlights
55 data points| Revenue | $63.63B |
| Cost of Revenue | $17.85B |
| Gross Profit | $45.78B |
| SG&A Expenses | $14.73B |
| Interest Expense | $3.09B |
| Net Income | $8.03B |
| EPS (Basic) | $1.42 |
| EPS (Diluted) | $1.41 |
| Shares Outstanding (Basic) | 5.66B |
| Shares Outstanding (Diluted) | 5.70B |
Key Highlights
- 1Total revenues increased by 7% to $63.6 billion in 2024, driven by Paxlovid, the Seagen acquisition, Vyndaqel family, and Eliquis, partially offset by a decline in Comirnaty.
- 2The company is focused on four key priorities for 2025: improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation.
- 3Significant revenue declines were noted for Comirnaty (-53% operationally) and Paxlovid (-57% operationally), reflecting the transition from government contracts to commercial markets and fluctuating demand.
- 4The acquisition of Seagen in December 2023 is a major strategic move, expected to strengthen Pfizer's oncology portfolio and generate significant cost synergies.
- 5Pfizer is actively managing the impact of upcoming patent expirations, with a moderate impact expected in 2025 and a more significant impact anticipated between 2026 and 2030.
- 6The company acknowledges the ongoing pricing pressures from payors and governments, particularly in relation to the Inflation Reduction Act (IRA), which is expected to have a net unfavorable impact on revenue of approximately $1 billion in 2025.
- 7Pfizer continues to invest in its R&D pipeline, with a focus on oncology, internal medicine, vaccines, and inflammation & immunology, and has undertaken organizational changes to consolidate its R&D operations.